Research programme: oncolytic viruses - Introgen
Alternative Names: INGN 001; INGN 007; INGN 009; KD3-IFN; VRX 007; VRX 011; VRX-009Latest Information Update: 18 Feb 2010
At a glance
- Originator VirRx
- Developer Introgen Therapeutics
- Class Oncolytic viruses
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Mar 2008 INGN 007 is still in preclinical trials for various solid tumour indications in the US
- 06 Jan 2006 Preclinical data from a media release have been added to the adverse events and Cancer pharmacodynamics sections
- 15 Sep 2005 Preclinical data from a media release have been added to the adverse events section